Showing Protein Voltage-dependent calcium channel subunit alpha-2/delta-2 (HMDBP07485)

• 13193

1. Voltage-dependent calcium channel subunit alpha-2-2
2. Voltage-dependent calcium channel subunit delta-2
3. Voltage-gated calcium channel subunit alpha-2/delta-2

• 3-Methylthiofentanyl Action Pathway
• Acebutolol Action Pathway
• Alfentanil Action Pathway
• Alprenolol Action Pathway
• Alvimopan Action Pathway
• Amiodarone Action Pathway
• Amlodipine Action Pathway
• Anileridine Action Pathway
• Arbutamine Action Pathway
• Atenolol Action Pathway
• Benzocaine Action Pathway
• Betaxolol Action Pathway
• Bevantolol Action Pathway
• Bisoprolol Action Pathway
• Bopindolol Action Pathway
• Bupivacaine Action Pathway
• Bupranolol Action Pathway
• Buprenorphine Action Pathway
• Carfentanil Action Pathway
• Carteolol Action Pathway
• Carvedilol Action Pathway
• Chloroprocaine Action Pathway
• Citalopram Action Pathway
• Cocaine Action Pathway
• Codeine Action Pathway
• Desipramine Action Pathway
• Dezocine Action Pathway
• Dibucaine Action Pathway
• Dihydromorphine Action Pathway
• Diltiazem Action Pathway
• Dimethylthiambutene Action Pathway
• Diphenoxylate Action Pathway
• Disopyramide Action Pathway
• Dobutamine Action Pathway
• Epinephrine Action Pathway
• Escitalopram Action Pathway
• Esmolol Action Pathway
• Ethylmorphine Action Pathway
• Felodipine Action Pathway
• Felodipine Metabolism Pathway
• Fentanyl Action Pathway
• Flecainide Action Pathway
• Fluoxetine Action Pathway
• Fosphenytoin (Antiarrhythmic) Action Pathway
• Glibenclamide Action Pathway
• Gliclazide Action Pathway
• Heroin Action Pathway
• Hydrocodone Action Pathway
• Hydromorphone Action Pathway
• Ibutilide Action Pathway
• Imipramine Action Pathway
• Isoprenaline Action Pathway
• Isradipine Action Pathway
• Ketobemidone Action Pathway
• Labetalol Action Pathway
• Levallorphan Action Pathway
• Levobunolol Action Pathway
• Levobupivacaine Action Pathway
• Levomethadyl Acetate Action Action Pathway
• Levorphanol Action Pathway
• Lidocaine (Antiarrhythmic) Action Pathway
• Lidocaine (Local Anaesthetic) Action Pathway
• Mepivacaine Action Pathway
• Methadone Action Pathway
• Methadyl Acetate Action Pathway
• Metipranolol Action Pathway
• Metoprolol Action Pathway
• Mexiletine Action Pathway
• Morphine Action Pathway
• Muscle/Heart Contraction
• Nadolol Action Pathway
• Nalbuphine Action Pathway
• Naloxone Action Pathway
• Naltrexone Action Pathway
• Nateglinide Action Pathway
• Nebivolol Action Pathway
• Nicotine Action Pathway
• Nifedipine Action Pathway
• Nimodipine Action Pathway
• Nisoldipine Action Pathway
• Nitrendipine Action Pathway
• Oxprenolol Action Pathway
• Oxybuprocaine Action Pathway
• Oxycodone Action Pathway
• Oxymorphone Action Pathway
• Pancreas Function
• Penbutolol Action Pathway
• Pentazocine Action Pathway
• Phenytoin (Antiarrhythmic) Action Pathway
• Pindolol Action Pathway
• Practolol Action Pathway
• Prilocaine Action Pathway
• Procainamide (Antiarrhythmic) Action Pathway
• Procaine Action Pathway
• Proparacaine Action Pathway
• Propoxyphene Action Pathway
• Propranolol Action Pathway
• Quinidine Action Pathway
• Remifentanil Action Pathway
• Repaglinide Action Pathway
• Ropivacaine Action Pathway
• Sotalol Action Pathway
• Sufentanil Action Pathway
• Timolol Action Pathway
• Tocainide Action Pathway
• Tramadol Action Action Pathway
• Verapamil Action Pathway

1. Membrane
2. Single-pass type I membrane protein (Potential)

>3453 bp
ATGGCGGTGCCGGCTCGGACCTGCGGCGCCTCTCGGCCCGGCCCAGCGCGGACTGCGCGC
CCCTGGCCCGGCTGCGGCCCCCACCCTGGCCCCGGCACCCGGCGCCCGACGTCCGGGCCC
CCGCGCCCGCTGTGGCTGCTGCTGCCGCTTCTACCGCTGCTCGCCGCCCCCGGCGCCTCT
GCCTACAGCTTCCCCCAGCAGCACACGATGCAGCACTGGGCCCGGCGTCTGGAGCAGGAG
GTCGACGGCGTGATGCGGATTTTTGGAGGCGTCCAGCAGCTCCGTGAGATTTACAAGGAC
AACCGGAACCTGTTCGAGGTACAGGAGAATGAGCCTCAGAAGTTGGTGGAGAAGGTGGCA
GGGGACATTGAGAGCCTTCTGGACAGGAAGGTGCAGGCCCTGAAGAGACTGGCTGATGCT
GCAGAGAACTTCCAGAAAGCACACCGCTGGCAGGACAACATCAAGGAGGAAGACATCGTG
TACTATGACGCCAAGGCTGACGCTGAGCTGGACGACCCTGAGAGTGAGGATGTGGAAAGG
GGGTCTAAGGCCAGCACCCTAAGGCTGGACTTCATCGAGGACCCAAACTTCAAGAACAAG
GTCAACTATTCATACGCGGCTGTACAGATCCCTACGGACATCTACAAAGGCTCCACTGTC
ATCCTCAATGAGCTCAACTGGACAGAGGCCCTGGAGAATGTGTTCATGGAAAACCGCAGA
CAAGACCCCACACTGCTGTGGCAGGTCTTCGGCAGCGCCACAGGAGTCACTCGCTACTAC
CCGGCCACCCCGTGGCGAGCCCCCAAGAAGATCGACCTGTACGATGTCCGAAGGAGACCC
TGGTATATCCAGGGGGCCTCGTCACCCAAAGACATGGTCATCATCGTGGATGTGAGTGGC
AGTGTGAGCGGCCTGACCCTGAAGCTGATGAAGACATCTGTCTGCGAGATGCTGGACACG
CTGTCTGATGATGACTATGTGAATGTGGCCTCGTTCAACGAGAAGGCACAGCCTGTGTCA
TGCTTCACACACCTGGTGCAGGCCAATGTGCGCAACAAGAAGGTGTTCAAGGAAGCTGTG
CAGGGCATGGTGGCCAAGGGCACCACAGGCTACAAGGCCGGCTTTGAGTATGCCTTTGAC
CAGCTGCAGAACTCCAACATCACTCGGGCCAACTGCAACAAGATGATCATGATGTTCACG
GATGGTGGTGAGGACCGCGTGCAGGACGTCTTTGAGAAGTACAATTGGCCAAACCGGACG
GTGCGCGTGTTTACTTTCTCCGTGGGGCAGCATAACTATGACGTCACACCGCTGCAGTGG
ATGGCCTGTGCCAACAAAGGCTACTATTTTGAGATCCCTTCCATCGGAGCCATCCGCATC
AACACACAGGAATATCTAGATGTGTTGGGCAGGCCCATGGTGCTGGCAGGCAAGGAGGCC
AAGCAGGTGCAGTGGACCAACGTGTATGAGGATGCACTGGGACTGGGGTTGGTGGTAACA
GGGACCCTCCCTGTTTTCAACCTGACACAGGATGGCCCTGGGGAAAAGAAGAACCAGCTG
ATCCTGGGCGTGATGGGCATTGACGTGGCTCTGAATGACATCAAGAGGCTGACCCCCAAC
TACACGCTTGGAGCCAACGGCTATGTGTTTGCCATTGACCTGAACGGCTACGTGTTGCTG
CACCCCAATCTCAAGCCCCAGACCACCAACTTCCGGGAGCCTGTGACTCTGGACTTCCTG
GATGCGGAGCTAGAGGATGAGAACAAGGAAGAGATCCGTCGGAGCATGATTGATGGCAAC
AAGGGCCACAAGCAGATCAGAACGTTGGTCAAGTCCCTGGATGAGAGGTACATAGATGAG
GTGACACGGAACTACACCTGGGTGCCTATAAGGAGCACTAACTACAGCCTGGGGCTGGTG
CTCCCACCCTACAGCACCTTCTACCTCCAAGCCAATCTCAGTGACCAGATCCTGCAGGTC
AAGTTGCCAATCAGCAAACTGAAGGATTTTGAGTTCCTGCTCCCCAGCAGCTTTGAGTCT
GAAGGACACGTTTTCATTGCTCCCAGAGAGTACTGCAAGGACCTGAATGCCTCAGACAAC
AACACCGAGTTCCTGAAAAACTTTATTGAGCTCATGGAGAAAGTGACTCCAGACTCCAAG
CAGTGCAACAACTTCCTTCTGCACAACCTGATCTTGGACACGGGCATCACGCAGCAGCTG
GTAGAGCGTGTGTGGAGGGACCAGGATCTCAACACGTACAGCCTACTGGCCGTGTTCGCT
GCCACAGACGGTGGCATCACCCGAGTCTTCCCCAACAAGGCAGCTGAGGACTGGACAGAG
AACCCTGAGCCCTTCAATGCCAGCTTCTACCGCCGCAGCCTGGATAACCACGGTTATGTC
TTCAAGCCCCCACACCAGGATGCCCTGTTAAGGCCGCTGGAGCTGGAGAATGACACTGTG
GGCATCCTCGTCAGCACAGCTGTGGAGCTCAGCCTAGGCAGGCGCACACTGAGGCCAGCA
GTGGTGGGCGTCAAGCTGGACCTAGAGGCTTGGGCTGAGAAGTTCAAGGTGCTAGCCAGC
AACCGTACCCACCAAGACCAGCCTCAGAAGTGCGGCCCCAACAGCCACTGTGAGATGGAC
TGCGAGGTTAACAATGAGGACTTACTCTGTGTCCTCATTGATGATGGAGGATTCCTGGTG
CTGTCAAACCAGAACCATCAGTGGGACCAGGTGGGCAGGTTCTTCAGTGAGGTGGATGCC
AACCTGATGCTGGCACTCTACAATAACTCCTTCTACACCCGCAAGGAGTCCTATGACTAT
CAGGCAGCCTGTGCCCCTCAGCCCCCTGGCAACCTGGGTGCTGCACCCCGGGGTGTCTTT
GTGCCCACCGTTGCAGATTTCCTTAACCTGGCCTGGTGGACCTCTGCTGCCGCCTGGTCC
CTGTTCCAGCAGCTTCTCTACGGCCTCATCTACCACAGCTGGTTCCAAGCAGACCCCGCG
GAGGCCGAGGGGAGCCCCGAGACGCGCGAGAGCAGCTGCGTCATGAAACAGACCCAGTAC
TACTTCGGCTCGGTAAACGCCTCCTACAACGCCATCATCGACTGCGGAAACTGCTCCAGG
CTGTTCCACGCGCAGAGACTGACCAACACCAATCTTCTCTTTGTGGTGGCCGAGAAGCCG
CTGTGCAGCCAGTGCGAGGCTGGCCGGCTGCTGCAGAAGGAGACGCACTCGGACGGCCCG
GAGCAGTGTGAGCTAGTGCAGAGACCGCGATACCGGAGAGGCCCGCACATCTGCTTCGAC
TACAACGCGACAGAAGATACCTCAGACTGTGGCCGCGGGGCCTCCTTCCCGCCGTCGCTG
GGCGTCCTGGTCTCCCTGCAACTGCTGCTCCTCCTGGGCCTGCCGCCCCGGCCGCAGCCT
CAAGTCCTCGTCCACGCCTCTCGCCGCCTCTGA

• VWA (PF00092 )
• Cache_1 (PF02743 )
• VGCC_alpha2 (PF08473 )
• VWA_N (PF08399 )

• 1-18

• 1114-1134

>Voltage-dependent calcium channel subunit alpha-2/delta-2
MAVPARTCGASRPGPARTARPWPGCGPHPGPGTRRPTSGPPRPLWLLLPLLPLLAAPGAS
AYSFPQQHTMQHWARRLEQEVDGVMRIFGGVQQLREIYKDNRNLFEVQENEPQKLVEKVA
GDIESLLDRKVQALKRLADAAENFQKAHRWQDNIKEEDIVYYDAKADAELDDPESEDVER
GSKASTLRLDFIEDPNFKNKVNYSYAAVQIPTDIYKGSTVILNELNWTEALENVFMENRR
QDPTLLWQVFGSATGVTRYYPATPWRAPKKIDLYDVRRRPWYIQGASSPKDMVIIVDVSG
SVSGLTLKLMKTSVCEMLDTLSDDDYVNVASFNEKAQPVSCFTHLVQANVRNKKVFKEAV
QGMVAKGTTGYKAGFEYAFDQLQNSNITRANCNKMIMMFTDGGEDRVQDVFEKYNWPNRT
VRVFTFSVGQHNYDVTPLQWMACANKGYYFEIPSIGAIRINTQEYLDVLGRPMVLAGKEA
KQVQWTNVYEDALGLGLVVTGTLPVFNLTQDGPGEKKNQLILGVMGIDVALNDIKRLTPN
YTLGANGYVFAIDLNGYVLLHPNLKPQTTNFREPVTLDFLDAELEDENKEEIRRSMIDGN
KGHKQIRTLVKSLDERYIDEVTRNYTWVPIRSTNYSLGLVLPPYSTFYLQANLSDQILQV
KLRISKLKDFEFLLPSSFESEGHVFIAPREYCKDLNASDNNTEFLKNFIELMEKVTPDSK
QCNNFLLHNLILDTGITQQLVERVWRDQDLNTYSLLAVFAATDGGITRVFPNKAAEDWTE
NPEPFNASFYRRSLDNHGYVFKPPHQDALLRPLELENDTVGILVSTAVELSLGRRTLRPA
VVGVKLDLEAWAEKFKVLASNRTHQDQPQKCGPNSHCEMDCEVNNEDLLCVLIDDGGFLV
LSNQNHQWDQVGRFFSEVDANLMLALYNNSFYTRKESYDYQAACAPQPPGNLGAAPRGVF
VPTVADFLNLAWWTSAAAWSLFQQLLYGLIYHSWFQADPAEAEGSPETRESSCVMKQTQY
YFGSVNASYNAIIDCGNCSRLFHAQRLTNTNLLFVVAEKPLCSQCEAGRLLQKETHSDGP
EQCELVQRPRYRRGPHICFDYNATEDTSDCGRGASFPPSLGVLVSLQLLLLLGLPPRPQP
QVLVHASRRL

1. Wollscheid B, Bausch-Fluck D, Henderson C, O'Brien R, Bibel M, Schiess R, Aebersold R, Watts JD: Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol. 2009 Apr;27(4):378-86. doi: 10.1038/nbt.1532. Epub 2009 Apr 6. [PubMed:19349973 ]
2. Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7. [PubMed:15489334 ]
3. Nagase T, Ishikawa K, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O: Prediction of the coding sequences of unidentified human genes. IX. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro. DNA Res. 1998 Feb 28;5(1):31-9. [PubMed:9628581 ]
4. Klugbauer N, Lacinova L, Marais E, Hobom M, Hofmann F: Molecular diversity of the calcium channel alpha2delta subunit. J Neurosci. 1999 Jan 15;19(2):684-91. [PubMed:9880589 ]
5. Gao B, Sekido Y, Maximov A, Saad M, Forgacs E, Latif F, Wei MH, Lerman M, Lee JH, Perez-Reyes E, Bezprozvanny I, Minna JD: Functional properties of a new voltage-dependent calcium channel alpha(2)delta auxiliary subunit gene (CACNA2D2). J Biol Chem. 2000 Apr 21;275(16):12237-42. [PubMed:10766861 ]
6. Hobom M, Dai S, Marais E, Lacinova L, Hofmann F, Klugbauer N: Neuronal distribution and functional characterization of the calcium channel alpha2delta-2 subunit. Eur J Neurosci. 2000 Apr;12(4):1217-26. [PubMed:10762351 ]
7. Gong HC, Hang J, Kohler W, Li L, Su TZ: Tissue-specific expression and gabapentin-binding properties of calcium channel alpha2delta subunit subtypes. J Membr Biol. 2001 Nov 1;184(1):35-43. [PubMed:11687876 ]
8. Klugbauer N, Marais E, Hofmann F: Calcium channel alpha2delta subunits: differential expression, function, and drug binding. J Bioenerg Biomembr. 2003 Dec;35(6):639-47. [PubMed:15000524 ]
9. Carboni GL, Gao B, Nishizaki M, Xu K, Minna JD, Roth JA, Ji L: CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity. Oncogene. 2003 Jan 30;22(4):615-26. [PubMed:12555074 ]
10. Lacinova L, Klugbauer N: Modulation of gating currents of the Ca(v)3.1 calcium channel by alpha 2 delta 2 and gamma 5 subunits. Arch Biochem Biophys. 2004 May 15;425(2):207-13. [PubMed:15111129 ]